DEPDC1B enhances malignant phenotypes of multiple myeloma through upregulating CCNB1 and inhibiting p53 signaling pathway
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DEPDC1B enhances malignant phenotypes of multiple myeloma through upregulating CCNB1 and inhibiting p53 signaling pathway
Authors
Keywords
-
Journal
TISSUE & CELL
Volume -, Issue -, Pages 102263
Publisher
Elsevier BV
Online
2023-11-05
DOI
10.1016/j.tice.2023.102263
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Diagnosis and Management of Multiple Myeloma
- (2022) Andrew J. Cowan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Smoldering multiple myeloma current treatment algorithms
- (2022) S. Vincent Rajkumar et al. Blood Cancer Journal
- CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine
- (2022) Xi Chen et al. Frontiers in Endocrinology
- Prognostic and predictive biomarker developments in multiple myeloma
- (2021) Craig T. Wallington-Beddoe et al. Journal of Hematology & Oncology
- MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma
- (2021) Peng Xia et al. Cell Death & Disease
- High Expression of DEPDC1 Promotes Malignant Phenotypes of Breast Cancer Cells and Predicts Poor Prognosis in Patients With Breast Cancer
- (2019) Huishan Zhao et al. Frontiers in Oncology
- Prognostic Value of DEPDC1 Expression in Tumor and Non-tumor Tissue of Patients With Hepatocellular Carcinoma
- (2019) MASATAKA AMISAKI et al. ANTICANCER RESEARCH
- DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma
- (2019) Chao Zhou et al. BIOSCIENCE REPORTS
- Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer
- (2018) Hui Zhang et al. JOURNAL OF CELLULAR PHYSIOLOGY
- DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis
- (2018) Di Qu et al. CANCER SCIENCE
- Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance
- (2018) Bowen Xie et al. CANCER LETTERS
- DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC
- (2018) Lei Zhang et al. CANCER LETTERS
- Targeted interfering DEP domain containing 1 protein induces apoptosis in A549 lung adenocarcinoma cells through the NF-κB signaling pathway
- (2017) Qingqing Wang et al. OncoTargets and Therapy
- DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/β-catenin signaling
- (2014) Yi Yang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The prognostic value of Cyclin B1 in pancreatic cancer
- (2014) Li Zhou et al. MEDICAL ONCOLOGY
- DEP domains: structurally similar but functionally different
- (2014) Sarah V. Consonni et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- cAMP regulates DEP domain-mediated binding of the guanine nucleotide exchange factor Epac1 to phosphatidic acid at the plasma membrane
- (2012) S. V. Consonni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cell-Permeable Peptide DEPDC1-ZNF224 Interferes with Transcriptional Repression and Oncogenicity in Bladder Cancer Cells
- (2010) Y. Harada et al. CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started